Literature DB >> 34233962

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Neeraj Sharma1, James B Smadbeck2, Nadine Abdallah3, Cinthya Zepeda-Mendoza4, Moritz Binder3, Kathryn E Pearce1, Yan W Asmann5, Jess F Peterson1,6, Rhett P Ketterling1,6, Patricia T Greipp1,6, P Leif Bergsagel7, S Vincent Rajkumar3, Shaji K Kumar3, Linda B Baughn1,6.   

Abstract

PURPOSE: Structural variants (SV) of the MYC gene region are common in multiple myeloma and influence disease progression. However, the prognostic significance of different MYC SVs in multiple myeloma has not been clearly established. EXPERIMENTAL
DESIGN: We conducted a retrospective study of multiple myeloma comparing MYC SV subtypes identified by next-generation sequencing (NGS) and FISH to MYC expression and disease survival using 140 cases from Mayo Clinic and 658 cases from the MMRF CoMMpass study.
RESULTS: MYC SVs were found in 41% of cases and were classified into nine subtypes. A correlation between the presence of a MYC SV and increased MYC expression was identified. Among the nine MYC subtypes, the non-immunoglobulin (non-Ig) insertion subtype was independently associated with improved outcomes, while the Ig insertion subtype, specifically involving the IgL gene partner, was independently associated with poorer outcomes compared with other MYC SV subtypes. Although the FISH methodology failed to detect approximately 70% of all MYC SVs, those detected by FISH were associated with elevated MYC gene expression and poor outcomes suggesting a different pathogenic role for FISH-detected MYC subtypes compared with other MYC subtypes.
CONCLUSIONS: Understanding the impact of different MYC SVs on disease outcome is necessary for the reliable interpretation of MYC SVs in multiple myeloma. NGS approaches should be considered as a replacement technique for a more comprehensive evaluation of the multiple myeloma clone. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34233962      PMCID: PMC8738776          DOI: 10.1158/1078-0432.CCR-21-0005

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Authors:  Brian A Walker; Konstantinos Mavrommatis; Christopher P Wardell; T Cody Ashby; Michael Bauer; Faith E Davies; Adam Rosenthal; Hongwei Wang; Pingping Qu; Antje Hoering; Mehmet Samur; Fadi Towfic; Maria Ortiz; Erin Flynt; Zhinuan Yu; Zhihong Yang; Dan Rozelle; John Obenauer; Matthew Trotter; Daniel Auclair; Jonathan Keats; Niccolo Bolli; Mariateresa Fulciniti; Raphael Szalat; Philippe Moreau; Brian Durie; A Keith Stewart; Hartmut Goldschmidt; Marc S Raab; Hermann Einsele; Pieter Sonneveld; Jesus San Miguel; Sagar Lonial; Graham H Jackson; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil Munshi; Anjan Thakurta; Gareth J Morgan
Journal:  Blood       Date:  2018-06-08       Impact factor: 22.113

3.  False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.

Authors:  Rebecca L King; Ellen D McPhail; Reid G Meyer; George Vasmatzis; Kathryn Pearce; James B Smadbeck; Rhett P Ketterling; Stephanie A Smoley; Patricia T Greipp; Nicole L Hoppman; Jess F Peterson; Linda B Baughn
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma.

Authors:  Hanne E H Møller; Birgitte S Preiss; Per Pedersen; Brian Østergaard; Mikael Frederiksen; Niels Abildgaard; Michael B Møller
Journal:  Eur J Haematol       Date:  2018-07-12       Impact factor: 2.997

6.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

7.  Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements.

Authors:  Jess F Peterson; Beth A Pitel; Stephanie A Smoley; George Vasmatzis; James B Smadbeck; Patricia T Greipp; Rhett P Ketterling; William R Macon; Linda B Baughn
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-06-03

8.  MYC dysregulation in the progression of multiple myeloma.

Authors:  Kristine Misund; Niamh Keane; Caleb K Stein; Yan W Asmann; Grady Day; Seth Welsh; Scott A Van Wier; Daniel L Riggs; Greg Ahmann; Marta Chesi; David S Viswanatha; Shaji K Kumar; Angela Dispenzieri; Veronica Gonzalez-Calle; Robert A Kyle; Michael O'Dwyer; S Vincent Rajkumar; K Martin Kortüm; J Jonathan Keats; Rafael Fonseca; A Keith Stewart; W Michael Kuehl; Esteban Braggio; P Leif Bergsagel
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

9.  Revealing the impact of structural variants in multiple myeloma.

Authors:  Ola Landgren; Francesco Maura; Even H Rustad; Venkata D Yellapantula; Dominik Glodzik; Kylee H Maclachlan; Benjamin Diamond; Eileen M Boyle; Cody Ashby; Patrick Blaney; Gunes Gundem; Malin Hultcrantz; Daniel Leongamornlert; Nicos Angelopoulos; Luca Agnelli; Daniel Auclair; Yanming Zhang; Ahmet Dogan; Niccolò Bolli; Elli Papaemmanuil; Kenneth C Anderson; Philippe Moreau; Hervé Avet-Loiseau; Nikhil C Munshi; Jonathan J Keats; Peter J Campbell; Gareth J Morgan
Journal:  Blood Cancer Discov       Date:  2020-09-15

10.  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Authors:  Brian A Walker; Konstantinos Mavrommatis; Christopher P Wardell; T Cody Ashby; Michael Bauer; Faith Davies; Adam Rosenthal; Hongwei Wang; Pingping Qu; Antje Hoering; Mehmet Samur; Fadi Towfic; Maria Ortiz; Erin Flynt; Zhinuan Yu; Zhihong Yang; Dan Rozelle; John Obenauer; Matthew Trotter; Daniel Auclair; Jonathan Keats; Niccolo Bolli; Mariateresa Fulciniti; Raphael Szalat; Phillipe Moreau; Brian Durie; A Keith Stewart; Hartmut Goldschmidt; Marc S Raab; Hermann Einsele; Pieter Sonneveld; Jesus San Miguel; Sagar Lonial; Graham H Jackson; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil Munshi; Anjan Thakurta; Gareth Morgan
Journal:  Leukemia       Date:  2018-07-02       Impact factor: 11.528

View more
  5 in total

Review 1.  Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.

Authors:  Julia Erin Wiedmeier-Nutor; Peter Leif Bergsagel
Journal:  Life (Basel)       Date:  2022-05-30

2.  Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Authors:  Parvathi Sudha; Aarif Ahsan; Karthik Ramasamy; Anjan Thakurta; Brian A Walker; Cody Ashby; Tasneem Kausar; Akhil Khera; Mohammad H Kazeroun; Chih-Chao Hsu; Lin Wang; Evelyn Fitzsimons; Outi Salminen; Patrick Blaney; Magdalena Czader; Jonathan Williams; Mohammad I Abu Zaid; Naser Ansari-Pour; Kwee L Yong; Frits van Rhee; William E Pierceall; Gareth J Morgan; Erin Flynt; Sarah Gooding; Rafat Abonour
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

Review 3.  Pathogenesis and treatment of multiple myeloma.

Authors:  Peipei Yang; Ying Qu; Mengyao Wang; Bingyang Chu; Wen Chen; Yuhuan Zheng; Ting Niu; Zhiyong Qian
Journal:  MedComm (2020)       Date:  2022-06-02

4.  Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project.

Authors:  Oliver C Lomas; Sarah Gooding; Maite Cabes; Helene Dreau; Edward Wilson; Paolo Polzella; Karthik Ramasamy; Angela D Hamblin
Journal:  EJHaem       Date:  2021-08-26

5.  MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma.

Authors:  Linda B Baughn; Jess F Peterson; Marie-France Gagnon; Kathryn E Pearce; Patricia T Greipp; Xinjie Xu; Nicole L Hoppman; Rhett P Ketterling; Ellen D McPhail; Rebecca L King
Journal:  Blood Cancer J       Date:  2021-11-24       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.